Central nervous system penetration of antiretroviral drugs: pharmacokinetic, pharmacodynamic and pharmacogenomic considerations

Clinical Pharmacokinetics
Eric H DecloedtJ A Joska

Abstract

The prevalence of HIV-associated neurocognitive disorder (HAND) is increasing despite the widespread use of combination antiretroviral therapy (ART). Initial reports suggest that the use of antiretrovirals with good central nervous system (CNS) penetration leads to better neurocognitive outcomes, but this has not yet been confirmed in a large cohort study or randomised controlled trial. There is emerging evidence that high CNS concentrations of some antiretrovirals are potentially neurotoxic and may be associated with the development of HAND. Antiretroviral CNS exposure is ideally determined by determining the ratio of cerebrospinal fluid (CSF):plasma area under the curve of unbound drug, but usually only total drug concentrations are measured and the ratio of CSF:plasma drug concentration is done at a single time point, which can result in misclassifying CNS penetration ability. Efavirenz was previously thought to have poor CNS penetration, measured by the CSF:plasma ratio (0.87%), but when unbound concentrations were measured it was found to have good CNS penetration (85%). Indinavir and efavirenz are the only antiretroviral drugs for which CNS area under the concentration-time curves using unbound plasma and CSF concentratio...Continue Reading

References

Jan 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·C Cordon-CardoJ R Bertino
Jun 1, 1997·Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association·R M HoetelmansJ H Beijnen
Jul 1, 1997·Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association·B RolinskiF D Goebel
Feb 25, 1998·Journal of Neurovirology·D R Groothuis, R M Levy
Mar 12, 1998·Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association·S J HaworthL M Dunkle
Nov 14, 1998·AIDS·R H EntingP Portegies
Feb 3, 1999·Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association·F AweekaR W Price
Mar 4, 1999·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·G J MoyleN Buss
Aug 24, 1999·Journal of Acquired Immune Deficiency Syndromes : JAIDS·S KravcikD W Cameron
Aug 3, 2002·CNS Drugs·Heather E WynnCourtney V Fletcher
Jun 25, 2003·Antimicrobial Agents and Chemotherapy·David W HaasJulie Stone
Oct 31, 2003·AIDS Research and Human Retroviruses·Marta BoffitoVeronica Miller
Dec 8, 2004·Journal of Neuroimmunology·Malcolm J AvisonJoseph R Berger
Feb 18, 2005·NeuroRx : the Journal of the American Society for Experimental NeuroTherapeutics·Hiroyuki Kusuhara, Yuichi Sugiyama
May 27, 2005·Antimicrobial Agents and Chemotherapy·Edmund V CapparelliJ Allen McCutchan
Jul 19, 2005·Nature Reviews. Neuroscience·Wolfgang Löscher, Heidrun Potschka
Nov 17, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Andrea AntinoriStephen C Piscitelli
Feb 8, 2006·The Pharmacogenomics Journal·S Rodríguez-NóvoaV Soriano
May 20, 2006·Scandinavian Journal of Infectious Diseases·Olle KarlströmAnders Sönnerborg
Jun 6, 2008·Clinical Pharmacology and Therapeutics·C D CroppK M Giacomini
Jul 11, 2008·Clinical Pharmacology and Therapeutics·S U YasudaS-M Huang
Dec 4, 2008·AIDS·Brookie M BestUNKNOWN CHARTER Group
Feb 25, 2009·Pharmacogenetics and Genomics·Julia di IulioUNKNOWN Swiss HIV Cohort Study
Mar 27, 2009·AIDS Research and Human Retroviruses·Aylin YilmazMagnus Gisslén

❮ Previous
Next ❯

Citations

Feb 2, 2016·The Journal of Clinical Investigation·J Victor Garcia
Oct 16, 2015·Journal of Neuropathology and Experimental Neurology·Brigid K JensenJudith B Grinspan
Aug 21, 2016·Toxicology Letters·Nádia M GriloSofia A Pereira
Jan 3, 2018·Current Opinion in Infectious Diseases·Roland NauHelmut Eiffert
Feb 9, 2019·Current HIV/AIDS Reports·Rebecca T VeenhuisLucio Gama
Dec 4, 2019·AIDS·Andrea MastrangeloPaola Cinque
Sep 13, 2019·Journal of Neuroimmune Pharmacology : the Official Journal of the Society on NeuroImmune Pharmacology·Jordan G SchnollKimberly M Christian
Dec 12, 2019·Journal of Neuroimmune Pharmacology : the Official Journal of the Society on NeuroImmune Pharmacology·Tyler LanmanRonald Ellis
Jun 17, 2016·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Willem-Martin GerberDerrick P Smit
May 5, 2017·AIDS·Sam Nightingale, Alan Winston
Nov 11, 2017·The Journal of Antimicrobial Chemotherapy·Malon Van den HofDasja Pajkrt
May 11, 2020·Current HIV/AIDS Reports·Veronica Obregon-PerkoAnn Chahroudi
Apr 9, 2016·The Journal of Biological Chemistry·Kyle W AndersonIrina A Pikuleva
Jul 22, 2019·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Pan-Fen WangEvan D Kharasch
Feb 22, 2018·Clinical Pharmacokinetics·Nithya SrinivasAngela D M Kashuba
May 1, 2021·Cells·Laura CheneyJoan W Berman
Jul 2, 2021·Biochimica Et Biophysica Acta. Molecular Basis of Disease·Lukas CervenyFrantisek Staud
Jul 20, 2021·Journal of Neuroimmunology·Monray E WilliamsPetrus J W Naudé

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Brain Barrier Chips

The blood brain barrier (BBB) is comprised of endothelial cells that regulate the influx and outflux of plasma concentrations. Lab-on-a-chip devices allow scientists to model diseases and mechanisms such as the passage of therapeutic antibodies across the BBB. Discover the latest research on BBB chips here.

Blood Brain Barrier Regulation in Health & Disease

The blood brain barrier is essential in regulating the movement of molecules and substances in and out of the brain. Disruption to the blood brain barrier and changes in permeability allow pathogens and inflammatory molecules to cross the barrier and may play a part in the pathogenesis of neurodegenerative disorders. Here is the latest research in this field.

Blood-Brain Barrier Transport in Neurodegeneration

The blood brain barrier is important for regulating the movement of biomolecules in and out of the brain. For example, membrane transporters in the blood brain barrier can be essential for regulating drug movement and dysregulation of these processes may play a role in neurodegeneration. This feed follows the latest research on this topic.

CSF & Lymphatic System

This feed focuses on Cerebral Spinal Fluid (CSF) and the lymphatic system. Discover the latest papers using imaging techniques to track CSF outflow into the lymphatic system in animal models.

Blood Brain Barrier

The blood brain barrier is a border that separates blood from cerebrospinal fluid. Discover the latest search on this highly selective semipermeable membrane here.

Related Papers

The Journal of Antimicrobial Chemotherapy
Brookie M BestCHARTER Group
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
Ronald J EllisJ Allen McCutchan
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
Andrea CalcagnoStefano Bonora
© 2021 Meta ULC. All rights reserved